- Tarceva - $564.2 million
- Xeloda - $647.6 million
- Velcade - $692.7 million
- Erbitux - $703.3 million
- Alimta - $1.04 billion
- Eloxatin - $1.2 billion
- Gleevec - $1.51 billion
- Herceptin - $1.66 billion
- Avastin - $2.66 billion
- Rituxan - $3 billion
- Top 10 Best-selling Cancer Drugs
- Top 10 Pharma CEO Salaries of 2011
- Robert Parkinson - Baxter
- Lamberto Andreotti - Bristol-Myers Squibb
- John Martin - Gilead
- Joseph Jimenez - Novartis
- John Lechleiter - Eli Lilly
- Kevin Sharer - Amgen
- Robert Coury - Mylan
- Miles White - Abbott Laboratories
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What’s your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- PneumRx, Inc. Acquires Key Assets From Broncus
- BIOTRONIK Announces Positive Results for the Passeo-18 Lux Peripheral Vascular Paclitaxel Releasing Balloon
- Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
- AngioDynamics Appoints Experienced Industry Executive as Chief Technology Officer
- Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
- More Press Releases
Latest Commentary